The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
Abstract
Purpose: To characterize the number and functional status of CD4+CD25+ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2). Patients and Methods: Patients with MM or RCC treated with high-dose bolus IL-2 (600,000 IU/kg every 8 hours) at a single center provided pre- and post-treatment whole blood specimens. Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation, separated into cellular subsets, and analyzed by flow cytometry or used for in vitro proliferation assays. Results: Between September 2003 and July 2005 57 patients were enrolled in the study with 48 patients available for analysis (45 MM, 12 RCC). Tregs were defined as CD4+CD25 hi T cells, and this subset was significantly elevated in the cancer patients compared with normal donors (7.75% v 2.24%). The CD4+CD25 hi T-cell pool in the patients constitutively expressed intracellular FoxP3, CTLA-4, and produced high amounts of IL-10. The Tregs were CCR7+ with 50% representing naïve and 50% central-memory T cells. The cells were functionally suppressive in mixed in vitro proliferation assays. Following IL-2 administration, the number and frequency of Tregs increased in patients with progressive disease but returned to normal levels in patients with objective clinical responses. Conclusion: The number of Tregs, defined as CD4+CD25 hi T cells is increased in patients with MM and RCC. High-dose IL-2 resulted in a significant decrease of Tregs in those patients achieving an objective clinical response to IL-2 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C., & Horak, I. (1993) · Cell · doi:10.1016/0092-8674(93)80067-o · Cited by 1,744
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., & Schuler, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1303 · Cited by 1,139
McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.206 · Cited by 820
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F., & Korangy, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3232 · Cited by 642
Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R., & Edinger, M. (2004) · Blood · doi:10.1182/blood-2004-01-0086 · Cited by 494
Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003) · PubMed · Cited by 489
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484
Biology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475
Understanding the generation and function of memory T cell subsets
Lanzavecchia, A., & Sallusto, F. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.04.010 · Cited by 462
Sadlack, B., Löhler, J., Schorle, H., Klebb, G., Haber, H., Sickel, E., Noelle, R. J., & Horak, I. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251111 · Cited by 423
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Atkins, M. B., Regan, M. M., McDermott, D. F., Mier, J. W., Stanbridge, E. J., Youmans, A. J., Febbo, P. G., Upton, M. P., Lechpammer, M., & Signoretti, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2019 · Cited by 402
The main function of IL-2 is to promote the development of T regulatory cells
Malek, T. R. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603272 · Cited by 327
Wang, E., Miller, L. D., Ohnmacht, G. A., D, S. M. M., Pérez‐Díez, A., Petersen, D. W., Zhao, Y., Simon, R., Powell, J. I., Asaki, E., et al. (2002) · PubMed · Cited by 260
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff, A., Kaufmann, M., Kaluza, B., Bartke, I., Zirngibl, H., Hein, R., Stolz, W., & Buettner, R. (1997) · PubMed · Cited by 227
Gurney, A. L., Marsters, S. A., Huang, A., Pitti, R. M., Mark, M., Baldwin, D. T., Gray, A. M., Dowd, P., Brush, J., Heldens, S., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80093-1 · Cited by 189
Kwon, B., Yu, K.-Y., Ni, J., Yu, G.-L., Jang, I.-K., Kim, Y.-J., Xing, L., Liu, D., Wang, S.-X., & Kwon, B. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6056 · Cited by 181
Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL‐)two to tango
Scheffold, A., Hühn, J., & Höfer, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200425887 · Cited by 168
Interleukin-2: Clinical applications
Atkins, M. B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33077 · Cited by 156
Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4
Sadlack, B., Kühn, R., Schorle, H., Rajewsky, K., Müller, W., & Horak, I. D. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240144 · Cited by 136
Rubin, J. T., Elwood, L. J., Rosenberg, S. A., & Lotze, M. T. (1989) · PubMed · Cited by 135
IL‐10‐Producing T Regulatory Type 1 Cells and Oral Tolerance
Battaglia, M., Gianfrani, C., Gregori, S., & RONCAROLOA, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1309.031 · Cited by 106
Donor-specific transplantation tolerance: The paradoxical behavior of CD4 + CD25 + T cells
Graça, L., Moine, A. L., Lin, C., Fairchild, P. J., Cobbold, S. P., & Waldmann, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400084101 · Cited by 104
Rabkin, C. S., Yang, Q., Goedert, J. J., Nguyen, G. T., Mitsuya, H., & Sei, S. (1999) · Blood · doi:10.1182/blood.v93.6.1838.406k39_1838_1842 · Cited by 100
Evaluation of melanin-related metabolites as markers of melanoma progression
Horikoshi, T., Ito, S., Wakamatsu, K., Onodera, H., & Eguchi, H. (1994) · Cancer · Cited by 77
In vitro studies with bendamustine: Enhanced activity in combination with rituximab
Rummel, M., Chow, K. U., Hoelzer, D. F., Mitrou, P. S., & Weidmann, E. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34873 · Cited by 73
Marincola, F. M., Venzon, D. J., White, D., Rubin, J. T., Lotze, M. T., Simonis, T. B., Balkissoon, J., Rosenberg, S. A., & Parkinson, D. R. (1992) · PubMed · Cited by 51
Cytokine Polymorphism and Its Possible Impact on Cancer
Jin, P., Panelli, M. C., Marincola, F. M., & Wang, E. (2004) · Immunologic Research · doi:10.1385/ir:30:2:181 · Cited by 35
Mature Dendritic Cells Induce Tumor-Specific Type 1 Regulatory T Cells
Lundqvist, A., Palmborg, A., Pavlenko, M., Levitskaya, J., & Pisa, P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000158854.15664.c2 · Cited by 21
Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
Cited by
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Metadata
- Authors
- Cesana, G. C., DeRaffele, G., Cohen, S., Moroziewicz, D., Mitcham, J., Stoutenburg, J., Cheung, K., Hesdorffer, C., Kim-Schulze, S., & Kaufman, H. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-03-01
- Volume
- 24
- Issue
- 7
- Pages
- 1169-1177
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139276825
- Cited by
- 349
- References
- 42
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.